GlaxoSmithKline Articles
Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs
13 May 2013
Merck & Co's Gardasil and GSK's Cervarix to be available to developing countries via UNICEF tender
9 May 2013
GlaxoSmithKline and Avalon Ventures in first-of-its-kind program to fuel early-stage innovation
24 April 2013
UK's OFT accuses GlaxoSmithKline of "market abuse"
19 April 2013
Patent briefs: Yaz patent invalid; FDA bars generic OxyContin; Appeals court backs GSK over Arzerra
17 April 2013
USA FDA seeks clarification on Discovery Labs' Surfaxin; issues briefing papers on GSK's Breo Ellipta
15 April 2013
Adult vaccines market controlled by GSK and Merck
15 April 2013
Briefs: Eddingpharm deal with GSK China for Tykerb; AEterna Zentaris and Ergomed link on AEZS-108
10 April 2013
UK govt launches review of business-university growth opportunities, to be led by GlaxoSmithKline CEO
10 April 2013
Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity
4 April 2013
Roche expands access to clinical trial data
28 February 2013
GSK pays $7.5 million milestone to Isis Pharma under antisense deal; says FDA accepts Anoro Ellipta NDA
20 February 2013
Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir
18 February 2013
BRIC countries' breast cancer market to see 8% annual growth to 2017
14 February 2013
Five new drugs for myelodysplastic syndromes set to launch by 2018
10 February 2013
Merck & Co prevails in patent fight over Zetia and Vytorin; GSK files for EU approval of melanoma products
8 February 2013
Treatment landscape for thyroid carcinoma will change dramatically through 2021; report
5 February 2013
GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma
4 February 2013
Another stumbling block for Impax Pharma's Rytary
22 January 2013
Japan's seasonal flu vaccines market analysis
16 January 2013
Pfizer's Quillivant XR oral suspension now available in USA; GlaxoSmithKline files BLA for albiglutide
15 January 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Flu vaccine innovation needed to protect children, says GlobalData health care expert
13 January 2013
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis
21 December 2012
News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus
20 December 2012
Regulatory briefs from GSK/Theravance, Allergan and Mylan
19 December 2012
US FDA approvals for Signifor, raxibacumab and Iclusig
17 December 2012
Mayne Pharma to acquire Kapanol in Australia from GlaxoSmithKline for up to A$14.0 million
16 December 2012
Great expectations for GlaxoSmithKline R&D newsflow
13 December 2012
Forest launches COPD product Tudorza in USA
12 December 2012
UT MD Anderson signs potentially lucrative deal with GlaxoSmithKline
10 December 2012
Big Pharma doing more for access to medicine in developing countries than two years ago
28 November 2012
Prognosis for renal cell carcinoma market development
27 November 2012
Asthma preventive drugs market led by GlaxoSmithKline's Advair
26 November 2012
News briefs: Japan clears filgrastim biosimilar; GSK to up stake in Nigerian and Indian firms; UCB deals
26 November 2012
Research shows diabetes drug rosiglitazone improves memory
21 November 2012
FDA backs new indication for GlaxoSmithKline's Promacta
20 November 2012
GlaxoSmithKline gives up on XenoPort Horizant collaboration
9 November 2012
GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab
6 November 2012
Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C
2 November 2012
Revised terms for ViiV Healthcare and Shionogi HIV partnership
30 October 2012
Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR
25 October 2012
Further initiatives from GlaxoSmithKline to help tackle global health challenges; TB deal with Aeras
12 October 2012
New LABA/LAMA drugs set to fracture COPD market
10 October 2012
AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor
8 October 2012
Teva/Impax generic Wellbutrin XL 300mg pulled from US market on non-bioequivalence grounds
4 October 2012
Milestone payments for Epizyme and Antares Pharma
3 October 2012
More highlights from ESMO Congress
2 October 2012
ESMO 2012 Congress highlights
1 October 2012
Top drugmakers set up non-profit TransCelerate to speed pharma R&D
20 September 2012
Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report
18 September 2012
News briefs from Threshold, Merck KGaA and GSK
18 September 2012
M&A briefs: GlaxoSmithKline/Response Genetics; Bayer/Teva unit
16 September 2012
Credit Suisse focus on new drugs for COPD
19 August 2012
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
